-
Will Actavis Win Competition For Allergan's Affection?
Thursday, October 16, 2014 - 10:10am | 839Read More...Four pharmaceutical companies have been flirting with merger deals. Discussing the confusing courting, Barron’s called them the Bob & Carol & Ted & Alice of pharmaceuticals, referencing the sexy 1969 comedy-drama with the tag line “Consider the Possibilities.” In...
-
Markets Little Changed Ahead Of 4th Of July Break
Wednesday, July 2, 2014 - 3:34pm | 2100Read More...U.S. stocks were little changed despite an ADP jobs report showing better-than-expected numbers. The ADP report comes ahead of the non-farm payrolls due on Thursday. Analysts are expecting the payrolls to confirm 212,000 jobs were added in June. The markets will close at 1:00 p.m. on Thursday...
-
JP Morgan Raises PT On Merck & Company To $44
Monday, May 2, 2011 - 5:04am | 27Read More...JP Morgan has raised the price target on Merck & Company (NYSE: MRK) from $42 to $44 and maintains its Overweight rating.
-
Jefferies Raises PT On Merck & Company To $34.50
Monday, February 14, 2011 - 7:51am | 27Read More...Jefferies & Company has raised the price target on Merck & Company (NYSE: MRK) from $29.90 to $34.50 and maintains its Hold rating.
-
Deutsche Bank Lowers MRK Target To $43, Reiterates Buy Rating
Friday, January 21, 2011 - 7:42am | 142Read More...In preparing its 4Q Preview and 2011 Outlook report, Deutsche Bank has lowered its PT on Merck & Company, Inc. (NYSE: MRK) from $48 to $43, and has reiterated its Buy rating. “While our EPS estimates remain the same, the vorapaxar disappointment had a $2-3 negative impact on our DCF valuation...
-
Deutsche Bank Lowers PT On Merck & Co.
Friday, January 21, 2011 - 7:10am | 27Read More...Deutsche Bank has lowered the price target on Merck & Co. (NYSE: MRK) from $48 to $43 and maintains its Buy rating.
-
FDA Asks Doctors To Suspend Use Of GlaxoSmithKline (GSK) Rotavirus Vaccine
Monday, March 22, 2010 - 2:37pm | 132Read More...The U.S. Food and Drug Administration announced on Monday that the agency has asked doctors to stop giving the GlaxoSmithKline PLC (NYSE: GSK) Rotarix vaccine on a temporary basis because extraneous viral components have been found in the vaccine. The GlaxoSmithKline PLC Rotarix vaccine is given to...
